CERUS CORP (CERS) Stock Price, Quote, News and Overview
NASDAQ:CERS - Nasdaq - US1570851014 - Common Stock - Currency: USD
CERS Quote, Performance and Key Statistics
1.27
-0.01 (-0.78%)
The current stock price of CERS is 1.27 USD. In the past month the price decreased by -17.53%. In the past year, price decreased by -45.84%.
CERS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ALC | ALCON INC | 29.29 | 43.91B | ||
| COO | COOPER COS INC/THE | 18.27 | 14.14B | ||
| SOLV | SOLVENTUM CORP | 12.06 | 12.41B | ||
| ALGN | ALIGN TECHNOLOGY INC | 14.51 | 9.89B | ||
| MMSI | MERIT MEDICAL SYSTEMS INC | 23.16 | 5.01B | ||
| LNTH | LANTHEUS HOLDINGS INC | 10.66 | 4.88B | ||
| BLCO | BAUSCH + LOMB CORP | 32.14 | 4.78B | ||
| HAE | HAEMONETICS CORP/MASS | 16.36 | 3.59B | ||
| ICUI | ICU MEDICAL INC | 18.25 | 3.14B | ||
| XRAY | DENTSPLY SIRONA INC | 8.51 | 2.85B | ||
| UFPT | UFP TECHNOLOGIES INC | 27.73 | 1.75B | ||
| ESTA | ESTABLISHMENT LABS HOLDINGS | N/A | 1.20B |
Related stock screener links
About CERS
Company Profile
Cerus Corp. engages in the research, development, and manufacturing of biomedical and surgical products. The company is headquartered in Concord, California and currently employs 281 full-time employees. The firm is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Company Info
CERUS CORP
1220 Concord Avenue
Concord CALIFORNIA 94520 US
CEO: William M. Greenman
Employees: 622
Phone: 19252886000
CERUS CORP / CERS FAQ
What is the stock price of CERUS CORP today?
The current stock price of CERS is 1.27 USD. The price decreased by -0.78% in the last trading session.
What is the ticker symbol for CERUS CORP stock?
The exchange symbol of CERUS CORP is CERS and it is listed on the Nasdaq exchange.
On which exchange is CERS stock listed?
CERS stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CERUS CORP stock?
10 analysts have analysed CERS and the average price target is 4.76 USD. This implies a price increase of 274.81% is expected in the next year compared to the current price of 1.27. Check the CERUS CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CERUS CORP worth?
CERUS CORP (CERS) has a market capitalization of 242.77M USD. This makes CERS a Micro Cap stock.
How many employees does CERUS CORP have?
CERUS CORP (CERS) currently has 622 employees.
What are the support and resistance levels for CERUS CORP (CERS) stock?
CERUS CORP (CERS) has a support level at 1.24 and a resistance level at 1.27. Check the full technical report for a detailed analysis of CERS support and resistance levels.
Is CERUS CORP (CERS) expected to grow?
The Revenue of CERUS CORP (CERS) is expected to grow by 24.23% in the next year. Check the estimates tab for more information on the CERS EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy CERUS CORP (CERS) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CERS, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CERS, evaluating the profitability, health, valuation and growth aspects
- CERUS CORP (CERS) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CERUS CORP (CERS) Sales and EPS estimates to see what analysts future expectations are.
- CERUS CORP (CERS) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CERUS CORP (CERS) Insider and Institutional Ownership to learn about the owners and their transactions.
- CERUS CORP (CERS) Stock Chart to make your own analysis
- CERUS CORP (CERS) Latest news and press-releases to stay up to date.
Does CERUS CORP (CERS) stock pay dividends?
CERS does not pay a dividend.
When does CERUS CORP (CERS) report earnings?
CERUS CORP (CERS) will report earnings on 2025-08-05, after the market close.
What is the Price/Earnings (PE) ratio of CERUS CORP (CERS)?
CERUS CORP (CERS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.1).
What is the Short Interest ratio of CERUS CORP (CERS) stock?
The outstanding short interest for CERUS CORP (CERS) is 4.05% of its float. Check the ownership tab for more information on the CERS short interest.
CERS Technical Analysis
CERS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CERS. CERS may be in some trouble as it scores bad on both profitability and health.
CERS Financial Highlights
Over the last trailing twelve months CERS reported a non-GAAP Earnings per Share(EPS) of -0.1. The EPS increased by 33.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -9.16% | ||
| ROE | -34.14% | ||
| Debt/Equity | 1.17 |
CERS Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to CERS. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 2.64% and a revenue growth 24.23% for CERS